Zimbabwe has turned down a substantial US healthcare agreement valued at $367m (£272m) over five years because of Washington's request for sensitive data.
This rejection was revealed following a internal memorandum from December was leaked, which showed Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesperson has since explained that the US was demanding access to genetic material for scientific study and commercial gain while refused to guarantee the resulting advantages from future treatments.
"We must now begin the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for further dialogue to find a deal suitable to all parties so the country's vital HIV treatment initiative can continue.
Wider Context
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a court blocked a related health funding agreement following concerns were filed about the safety of citizens' medical information.
After resuming office last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump claimed its spending was "inefficient" and his government was pursuing direct bilateral deals to enhance transparency and responsibility.
Based on statements, Sixteen nations in Africa have so far signed these new agreements, representing more than $18.3bn in new funding.
Details of the Rejected Deal
The money for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration could have provided significant advantages for Zimbabwean communities, particularly the 1.2 million presently on HIV treatment through American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, without any corresponding guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"Effectively, our country would provide the basic resources for scientific discovery with no certainty that the final treatments would be accessible to our population should a new health crisis arise."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its pursuit of one-on-one deals were undermining systems previously set up via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing system designed to manage future global health emergencies.
"This mechanism is intended to guarantee that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome further discussions with our US partners on how subsequent co-operation could be designed in a way that respects the independence and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the government's concerns, but suggested that negotiations need to persist considering much of the country's Aids initiatives were funded by foreign aid.
"Where technical issues arise, including those involving data governance or agreement terms, these can often be resolved through detailed discussion and negotiated safeguards," it added.
The halted deal underscores the ongoing challenges between receiving vital foreign assistance and safeguarding a country's data in an ever more data-driven world.